Muhammad A, van der Lely A J, Neggers S J C M M
Department of Medicine, Endocrinology section, Pituitary Centre Rotterdam, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Neth J Med. 2015 Oct;73(8):362-7.
In almost every patient, acromegaly is caused by a growth hormone secreting pituitary adenoma. Clinical features are the result of excessive growth hormone secretion and the consecutive excess in insulin-like growth factor I levels. This results in somatic overgrowth and metabolic disturbances with a higher morbidity and mortality than in the general population. With optimal disease management, mortality can be reduced to that seen in the general population. The current treatment of acromegaly is based on a combination of surgery, radiotherapy and medical therapy. This review provides an overview of the current and upcoming therapies with a focus on medical therapy.
几乎在每一位患者中，肢端肥大症都是由分泌生长激素的垂体腺瘤引起的。临床特征是生长激素分泌过多以及随之而来的胰岛素样生长因子I水平过高的结果。这导致身体过度生长和代谢紊乱，其发病率和死亡率高于普通人群。通过优化疾病管理，死亡率可降低至普通人群的水平。目前肢端肥大症的治疗基于手术、放疗和药物治疗的联合应用。本综述概述了当前及即将出现的治疗方法，重点是药物治疗。
